M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery Pharmaceutical Business ReviewUnder the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaceutical Business Review Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Read full story Post navigation Previous: FDA Selects Seven for PreCheck Pilot to Advance Drug ManufacturingNext: Roche’s KRAS drug tops its rivals in lung cancer trial Related Stories M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026 M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026